ES2155886T3 - Antagonistas super activos del vip. - Google Patents

Antagonistas super activos del vip.

Info

Publication number
ES2155886T3
ES2155886T3 ES95909489T ES95909489T ES2155886T3 ES 2155886 T3 ES2155886 T3 ES 2155886T3 ES 95909489 T ES95909489 T ES 95909489T ES 95909489 T ES95909489 T ES 95909489T ES 2155886 T3 ES2155886 T3 ES 2155886T3
Authority
ES
Spain
Prior art keywords
sup
vip
neurotransmission
sub
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909489T
Other languages
English (en)
Inventor
Terry W Moody
Illana Gozes
Douglas E Brenneman
Matityahu Fridkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yeda Research and Development Co Ltd
US Department of Health and Human Services
Original Assignee
Ramot at Tel Aviv University Ltd
Yeda Research and Development Co Ltd
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yeda Research and Development Co Ltd, US Department of Health and Human Services filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of ES2155886T3 publication Critical patent/ES2155886T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTA INVENCION SE REFIERE A UNA FAMILIA DE PEPTIDOS CODIFICANTES DE ANTAGONISTAS DE UN PEPTIDO VASOACTIVO INTESTINAL (VIP) DE FORMULA (I) DISEÑADO PARA DISTINGUIR MULTIPLES RECEPTORES QUE SON MEDIADORES EN LA NEUROTRANSMISION VIP, NEUROTROFISMO Y DIVISION CELULAR. LA INVENCION TAMBIEN SE REFIERE A METODOS PARA USAR ESTOS PEPTIDOS PARA CONTRARIAR LA FUNCION Y ACTIVIDAD VIP ASOCIADA. LA INVENCION SE REFIERE ADEMAS A COMPOSICIONES FARMACEUTICAS DISEÑADAS PARA INHIBIR LA ACTIVIDAD VIP ASOCIADA.EN LA FORMULA (I), R{SUP,1} Y R{SUP,2} SON MIEMBROS INDEPENDIENTES SELECCIONADOS DEL GRUPO COMPUESTO DE HIDROGENO, ALQUILO DE C{SUB,1} A C{SUB,20} Y ACILO DE C{SUB,1} A C{SUB,20}, CON LA CONDICION DE QUE AL MENOS UNO DE R{SUP,1} O R{SUP,2} SEA HIDROGENO; Y X{SUP,1} Y X{SUP,2} SON MIEMBROS SELECCIONADOS INDEPENDIENTEMENTE DEL GRUPO CONSISTENTE DE AMINOACIDOS QUE OCURREN NATURALMENTE Y AMINOACIDOS MIMETICOS.
ES95909489T 1994-02-07 1995-02-06 Antagonistas super activos del vip. Expired - Lifetime ES2155886T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/194,591 US5565424A (en) 1994-02-07 1994-02-07 Superactive VIP antagonists

Publications (1)

Publication Number Publication Date
ES2155886T3 true ES2155886T3 (es) 2001-06-01

Family

ID=22718168

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909489T Expired - Lifetime ES2155886T3 (es) 1994-02-07 1995-02-06 Antagonistas super activos del vip.

Country Status (11)

Country Link
US (1) US5565424A (es)
EP (1) EP0738280B1 (es)
JP (1) JP3588119B2 (es)
AT (1) ATE199160T1 (es)
AU (1) AU697829B2 (es)
CA (1) CA2182795C (es)
DE (1) DE69520092T2 (es)
DK (1) DK0738280T3 (es)
ES (1) ES2155886T3 (es)
IL (1) IL112557A (es)
WO (1) WO1995021194A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US6156725A (en) * 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
EP0835662B1 (en) * 1996-10-08 2001-11-14 National Institute of Immunology A drug for the treatment of cancer
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
CA2346866A1 (en) * 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
US6489297B1 (en) 2000-02-18 2002-12-03 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6608174B1 (en) 2000-02-18 2003-08-19 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
CA2405728A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
US20060075968A1 (en) * 2004-10-12 2006-04-13 Applied Materials, Inc. Leak detector and process gas monitor
AU2012259470B2 (en) 2011-02-02 2017-01-12 Emory University Antagonism of the VIP signaling pathway
US9458217B2 (en) * 2013-12-05 2016-10-04 Emory University Methods of managing graft versus host disease
ES2957890T3 (es) 2016-04-08 2024-01-29 Univ Emory Métodos de tratamiento del cáncer y las enfermedades infecciosas mediante terapias celulares
US11850263B2 (en) 2017-11-10 2023-12-26 Emory University Nanoparticles conjugated with vasoactive intestinal peptide antagonists
US11471506B2 (en) 2018-04-23 2022-10-18 Emory University VIP antagonists and uses in treating cancer
JP2022507688A (ja) * 2018-11-15 2022-01-18 エモリー ユニバーシティー 血管作用性小腸ペプチド（ｖｉｐ）アンタゴニストの組成物及び用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734400A (en) * 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5196315A (en) * 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
DE69101187T2 (de) * 1990-06-26 1994-09-29 Sanwa Kagaku Kenkyusho Co VIP-Analogen und ihre Verwendung.
US5217953A (en) * 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
IL99924A (en) * 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU1743895A (en) 1995-08-21
ATE199160T1 (de) 2001-02-15
DE69520092D1 (de) 2001-03-22
CA2182795C (en) 2007-11-06
IL112557A0 (en) 1995-05-26
AU697829B2 (en) 1998-10-15
EP0738280A1 (en) 1996-10-23
DE69520092T2 (de) 2001-08-02
JPH09511494A (ja) 1997-11-18
CA2182795A1 (en) 1995-08-10
DK0738280T3 (da) 2001-09-17
WO1995021194A1 (en) 1995-08-10
US5565424A (en) 1996-10-15
EP0738280B1 (en) 2001-02-14
IL112557A (en) 2000-02-17
JP3588119B2 (ja) 2004-11-10

Similar Documents

Publication Publication Date Title
ES2155886T3 (es) Antagonistas super activos del vip.
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
Fasciotto et al. Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture
ES2195361T3 (es) Peptido de union a integrina y uso del mismo.
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
AR053946A2 (es) Variante de alfa-amilasa de bacillus stearothermophilus original
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
AR019818A1 (es) Un inmunoconjugado de miostatina.
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
BR9711123A (pt) Quimeras de leucotoxina-gnrh
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
EA200200571A1 (ru) Новая композиция и ее применение
RS49517B (sr) PEPTID p277-ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRZE
FI970579A0 (fi) Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin
ATE322503T1 (de) Gefrierschutzprotein
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
KR850001774A (ko) Lh/rh길항성 펩티드의 제조방법
CO5050337A1 (es) Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma
DE69938130D1 (de) Neue peptide
NO20015398D0 (no) Endoparasitticidisk synergistisk kombinasjon inneholdende cykliske depsipeptider og piperaziner
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
KR920004417A (ko) 고나돌리베린 길항물질
SE8704272D0 (sv) Pharmaceutisk komposition
DE69530779D1 (de) Muramylpeptide zusammensetzungen für inhibierung von hiv replikation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 738280

Country of ref document: ES